CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
stage-ii
A collection of 17 issues
AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides
Skip to content
The CRC Digest
◇ RESEARCH
AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides
HistoNav, a deep-learning algorithm analyzing H&E-stained tissue samples from 2,095 patients, identified low-, intermediate-, and high-risk groups with 5-year disease-specific survival rates of 93.2%, 84.
Kazakhstan Study Links KRAS Mutation Detection Methods to Survival in Stage II-IV CRC
Skip to content
The CRC Digest
◇ RESEARCH
Kazakhstan Study Links KRAS Mutation Detection Methods to Survival in Stage II-IV CRC
A 332-patient cohort study compared KRAS variant detection by real-time and digital PCR in tumor tissue and plasma, examining associations with overall survival across stage II-IV disease. (Genes)
This content
Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer Surgery
A phase Ib trial evaluated the safety of combining trifluridine/tipiracil chemotherapy with radiation therapy before surgery in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)
CRC Research Update — August 19, 2026
Today's colorectal cancer research highlights
Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC
Skip to content
The CRC Digest
Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC
A multicenter real-world study from four Chinese hospitals evaluated long-term outcomes of a watch-and-wait strategy in stage II/III dMMR/MSI-H colorectal cancer patients who achieved endoscopic complete response after neoadjuvant anti-PD-1 monotherapy. (Frontiers in Immunology)
CRC Research Update — August 13, 2026
Today's colorectal cancer research highlights
Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment
The PROSPER trial will test lecithinized superoxide dismutase (PC-SOD) against placebo to prevent chemotherapy-induced peripheral neuropathy in stage II/III colorectal cancer patients receiving adjuvant mFOLFOX6, following promising phase II
CRC Research Update — August 06, 2026
Today's colorectal cancer research highlights
Study Examines Universal Tumor Screening for Lynch Syndrome in Japan
Skip to content
The CRC Digest
▪ SCREENING
Study Examines Universal Tumor Screening for Lynch Syndrome in Japan
A prospective study of 591 patients with stage II/III colorectal cancer in Japan aimed to clarify the clinical utility and cost-effectiveness of universal tumor screening using immunohistochemistry to identify Lynch syndrome, with